Meridian Bioscience Stock Forecast, Price & News

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

Is Meridian Bioscience a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Meridian Bioscience stock.
View analyst ratings for Meridian Bioscience or view top-rated stocks.

How has Meridian Bioscience's stock price been impacted by Coronavirus?

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VIVO stock has increased by 222.7% and is now trading at $20.75.
View which stocks have been most impacted by COVID-19.

Are investors shorting Meridian Bioscience?

Meridian Bioscience saw a drop in short interest in November. As of November 30th, there was short interest totaling 2,340,000 shares, a drop of 24.0% from the November 15th total of 3,080,000 shares. Based on an average trading volume of 386,300 shares, the short-interest ratio is presently 6.1 days. Currently, 5.5% of the company's stock are short sold.
View Meridian Bioscience's Short Interest.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, February 4th 2022.
View our earnings forecast for Meridian Bioscience.

How can I listen to Meridian Bioscience's earnings call?

Meridian Bioscience will be holding an earnings conference call on Friday, February 4th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) released its quarterly earnings results on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.03. The company earned $76.20 million during the quarter, compared to the consensus estimate of $68.40 million. Meridian Bioscience had a net margin of 22.46% and a trailing twelve-month return on equity of 23.61%. During the same period in the prior year, the business earned $0.19 earnings per share.
View Meridian Bioscience's earnings history.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY 2022 earnings guidance on Friday, December, 10th. The company provided earnings per share guidance of $0.980-$1.080 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.070. The company issued revenue guidance of $285 million-$300 million, compared to the consensus revenue estimate of $283.27 million.

What price target have analysts set for VIVO?

2 brokerages have issued 12 month price objectives for Meridian Bioscience's stock. Their forecasts range from $28.00 to $34.00. On average, they expect Meridian Bioscience's stock price to reach $31.00 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts' price targets for Meridian Bioscience or view top-rated stocks among Wall Street analysts.

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:

• John Patrick Kenny, Chief Executive Officer & Executive Director
• Julie Smith, Chief Accounting Officer, Senior VP & Controller
• Lourdes Weltzien, Executive Vice President-Life Science
• Tony Serafini-Lamanna, Executive Vice President-Diagnostics
• Charles Wood, VP-Corporate Strategy, Business Development & IR

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience CEO Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among Meridian Bioscience's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Meridian Bioscience's key competitors?

Some companies that are related to Meridian Bioscience include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), ICU Medical (ICUI), Neogen (NEOG), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all of VIVO's competitors.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Spire Wealth Management (0.01%). Company insiders that own Meridian Bioscience stock include Anthony P Bihl III, Bryan T Baldasare, Felicia Williams, John Mccune Jr Rice, John Mcilwraith and John P Kenny.
View institutional ownership trends for Meridian Bioscience.

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Meridian Bioscience company stock in the last year include Bryan T Baldasare, John Mccune Jr Rice, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience or view top insider-selling stocks.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was acquired by a variety of institutional investors in the last quarter, including Spire Wealth Management. Company insiders that have bought Meridian Bioscience stock in the last two years include Anthony P Bihl III, Bryan T Baldasare, Felicia Williams, John Mcilwraith, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience or or view top insider-buying stocks.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $20.75.

How much money does Meridian Bioscience make?

Meridian Bioscience has a market capitalization of $899.80 million and generates $317.90 million in revenue each year. The company earns $71.41 million in net income (profit) each year or $1.62 on an earnings per share basis.

How many employees does Meridian Bioscience have?

Meridian Bioscience employs 750 workers across the globe.

Does Meridian Bioscience have any subsidiaries?

The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.

When was Meridian Bioscience founded?

Meridian Bioscience was founded in 1977.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is www.meridianbioscience.com.

Where are Meridian Bioscience's headquarters?

Meridian Bioscience is headquartered at 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at (513) 271-3700, via email at [email protected], or via fax at 513-271-3762.